Tarsus Pharmaceuticals Inc (TARS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.96B
Last updated: Nov 17, 2026 at 11:06 AM ET
Tarsus Pharmaceuticals Inc (TARS) Earnings: Report Dates and Results
Tarsus Pharmaceuticals (TARS) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Tarsus Pharmaceuticals reported EPS of -$0.78, above the -$1.43 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TARS has an expected report date of Feb 22, 2027.
TARS Earnings Call
The latest TARS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 26 quarters below that had an estimate, TARS beat 17, missed 8 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $194.57M, up 63.9% from $118.70M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.78 | -$1.43 | N/A | +45.45% | Beat | N/A | 3 | 0 up, 0 down | Nov 3, 2026 | $194.57M |
| Jun 30, 2026 | -$0.43 | -$0.21 | -$0.28 - -$0.07 | -104.76% | Miss | N/A | 5 | 3 up, 1 down | Aug 6, 2026 | $173.91M |
| Mar 31, 2026 | -$0.16 | -$0.42 | -$0.57 - -$0.10 | +61.90% | Beat | N/A | 6 | 1 up, 2 down | May 6, 2026 | $162.05M |
| Dec 31, 2025 | -$0.20 | -$0.08 | -$0.09 - $0.07 | -139.23% | Miss | N/A | 6 | 1 up, 0 down | Feb 23, 2026 | $151.67M |
| Sep 30, 2025 | -$0.30 | -$0.33 | -$0.39 - -$0.28 | +9.09% | Beat | N/A | 4 | 0 up, 1 down | Nov 4, 2025 | $118.70M |
| Jun 30, 2025 | -$0.48 | -$0.36 | -$0.48 - -$0.18 | -33.33% | Miss | N/A | 3 | 0 up, 1 down | Aug 6, 2025 | $102.66M |
| Mar 31, 2025 | -$0.64 | -$0.63 | -$0.65 - -$0.61 | -1.59% | Miss | N/A | 2 | 0 up, 1 down | May 1, 2025 | $78.33M |
| Dec 31, 2024 | -$0.60 | -$0.82 | -$1.04 - -$0.48 | +26.44% | Beat | N/A | 3 | 0 up, 0 down | Feb 25, 2025 | $66.41M |
| Sep 30, 2024 | -$0.61 | -$1.00 | -$1.10 - -$0.82 | +39.00% | Beat | N/A | 8 | 1 up, 0 down | Nov 13, 2024 | $48.12M |
| Jun 30, 2024 | -$0.83 | -$0.80 | -$1.10 - -$0.57 | -3.75% | Miss | N/A | 9 | 2 up, 0 down | Aug 8, 2024 | $40.81M |
| Mar 31, 2024 | -$0.99 | -$1.25 | -$1.32 - -$0.89 | +20.80% | Beat | N/A | 8 | 2 up, 0 down | May 8, 2024 | $27.61M |
| Dec 31, 2023 | -$1.31 | -$1.36 | -$1.72 - -$1.08 | +3.68% | Beat | N/A | 9 | 1 up, 0 down | Feb 27, 2024 | $13.08M |
| Sep 30, 2023 | -$1.27 | -$1.27 | -$1.78 - -$1.19 | 0.00% | In line | N/A | 6 | 0 up, 1 down | Nov 9, 2023 | $1.87M |
| Jun 30, 2023 | -$1.17 | -$1.02 | -$1.23 - -$0.98 | -14.71% | Miss | N/A | 6 | 0 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$0.87 | -$0.91 | -$1.16 - -$0.82 | +4.40% | Beat | N/A | 4 | 1 up, 0 down | May 9, 2023 | $2.50M |
| Dec 31, 2022 | -$0.49 | -$0.69 | -$0.74 - -$0.61 | +28.99% | Beat | N/A | 4 | 0 up, 0 down | Mar 13, 2023 | $10.00M |
| Sep 30, 2022 | -$0.84 | -$1.07 | -$1.68 - -$0.67 | +21.50% | Beat | N/A | 6 | 0 up, 0 down | Nov 9, 2022 | N/A |
| Jun 30, 2022 | -$0.22 | -$0.50 | N/A | +56.00% | Beat | -166.7% | N/A | 0 up, 0 down | Aug 11, 2022 | $15.28M |
| Mar 31, 2022 | -$0.96 | -$1.06 | -$1.45 - -$0.16 | +9.43% | Beat | -304.3% | 6 | 0 up, 1 down | May 10, 2022 | $539000 |
| Dec 31, 2021 | -$0.72 | -$0.73 | -$0.85 - -$0.57 | +1.37% | Beat | N/A | 5 | 0 up, 0 down | Mar 14, 2022 | $338000 |
| Sep 30, 2021 | -$0.76 | -$0.47 | -$0.71 - $0.04 | -61.70% | Miss | N/A | 3 | N/A | Nov 9, 2021 | $1.24M |
| Jun 30, 2021 | $0.33 | -$0.33 | -$0.76 - -$0.16 | +200.00% | Beat | N/A | 3 | N/A | Aug 4, 2021 | $22.02M |
| Mar 31, 2021 | $0.47 | -$0.13 | N/A | +461.54% | Beat | N/A | 2 | N/A | May 11, 2021 | $33.43M |
| Dec 31, 2020 | -$0.68 | -$0.66 | -$0.69 - -$0.60 | -3.03% | Miss | N/A | 4 | N/A | Mar 31, 2021 | N/A |
| Sep 30, 2020 | -$0.50 | -$0.54 | -$0.58 - -$0.50 | +7.41% | Beat | N/A | 3 | N/A | Oct 16, 2020 | N/A |
| Jun 30, 2020 | -$0.19 | -$0.46 | N/A | +57.63% | Beat | N/A | N/A | N/A | Sep 2, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.62, after -$3.03 the year before. It was -$1.37 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.62 | N/A |
| Dec 31, 2024 | -$3.03 | N/A |
| Dec 31, 2023 | -$4.62 | N/A |
| Dec 31, 2022 | -$2.51 | N/A |
| Dec 31, 2021 | -$0.68 | N/A |
| Dec 31, 2020 | -$1.37 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,600 words across 17 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,636 | 17 | |
| 2026Q2 | Jun 30, 2026 | 5,924 | 15 | |
| 2026Q1 | Mar 31, 2026 | 6,067 | 13 | |
| 2025Q4 | Dec 31, 2025 | 6,119 | 14 | |
| 2025Q3 | Sep 30, 2025 | 5,560 | 13 | |
| 2025Q2 | Jun 30, 2025 | 5,532 | 12 | |
| 2025Q1 | Mar 31, 2025 | 5,603 | 11 | |
| 2024Q4 | Dec 31, 2024 | 7,868 | 14 |
2026Q3 Earnings Call
Opening remarks
David Nakasone Head of Investor Relations Thank you. Before we begin, I encourage everyone to visit the Investors section of the Tarsus website to view the press release issued today and related materials we will be discussing today. Joining me on the call today are Bobby Azamian, Chief Executive Officer and Chairman; Neera Clase, our Chief Commercial Officer; Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer; and joining us for Q&A is Dr. Liz Yeu, our Chief Medical Officer, and Sesha Neervannan, our Chief Operating Officer. I'd like to draw your attention to Slide 3, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional details. With that, I will turn the call over to Bobby.
Bobak Azamian CEO and Chairman Good afternoon, and thank you for joining us. 1 million, $1 billion, 5 and 5. More than 1 million bottles of XDEMVY dispensed, more than $1 billion in cumulative net product sales, and a pipeline with the potential to bring 5 new medicines to patients in the next 5 years. As we celebrate our 10th anniversary, those numbers say a lot about how far Tarsus has come. But what excites me the most is what they tell us about where we can go. We started with a conviction that there were important diseases in eye care hiding in plain sight and that following the science to their root cause could lead to entirely new categories of medicine. XDEMVY showed what that conviction could accomplish. This quarter, we delivered record sales and are again raising our full-year outlook. Neera and Jeff will take you through the details and why we believe XDEMVY is just getting started. I want to talk about our broader ambition: building the next leader in eye care, not one defined by a single drug, but by a repeatable ability to spot a disease the field has overlooked, bring forward a medicine that could change how it's treated, and bring it to patients. That's the standard we're applying across our pipeline. We want to be first or best, and we're treating opportunities where we believe we can make a meaningful difference. With Stargardt disease, that means the potential to help children and young adults preserve vision they would otherwise lose. With IRX-101, it means improving antiseptic preparation for patients receiving repeated retinal injections. And with our existing investigational programs for ocular rosacea and Lyme disease prevention, we have opportunities to address other diseases where patients still need better answers.
Frequently Asked Questions About TARS
When is Tarsus Pharmaceuticals's next earnings date?
Tarsus Pharmaceuticals's next earnings report is expected for Feb 22, 2027.
Did TARS beat earnings estimates last quarter?
Yes. Tarsus Pharmaceuticals reported EPS of -$0.78 for the quarter ended Sep 30, 2026, above the -$1.43 estimate, a 45.45% surprise.
What EPS do analysts expect from TARS next quarter?
The consensus EPS estimate for Tarsus Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.20 from 12 analysts, with estimates from -$0.58 to $0.15.
How often does TARS beat earnings estimates?
Tarsus Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -17.00%.
TARS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors